Industry news

Import ban extended as India's Pan Pharma racks up third FDA warning letter

Joseph Keenan / Fierce Biotech

The FDA posted another warning letter to Pan Pharmaceuticals that further extends an import alert issued last year, effectively keeping in place a ban on the drugmaker’s products in the U.S.

Liquid Biopsy Market Size to Reach $5.96 Billion by 2030: Grand View Research, Inc.

PRNewswire

Global liquid biopsies market is anticipated to reach 5,958.3 million by 2030, according to a new report by Grand View Research, Inc. As these less invasive biopsies are able to address a number of significant challenges associated with conventional biopsies such as, high level of invasiveness, incompleteness of cancer information that is acquired, associated post-biopsy serious medical complications, and subsequent cost inclusions. A growing need for more advanced, efficient and accurate method which provides a holistic view of the tumor and metastasis is the prime factor fueling rapid development of liquid biopsies.

Biopharma sector needs to try harder to get a passing grade

Peter Winter / BioWorld

The summer is over and industry executives and investors alike will be getting back to work in earnest for the final four months push until the end of the year. Both groups will be hoping for a much better period going forward. By all metrics the sector has struggled to build any sustained momentum that provides any confidence that it will close its books on 2016 in positive territory. What can we expect – more of the same, or a sudden resurgence in fortunes for the sector?

Gene diversity can alter metabolic individuality

John Fox / BioWorld

A new Japanese study of the effects of environmental and genetic influences on individual differences in proteomics and metabolomics has identified biomarkers for early disease prevention and diagnosis, through the identification and quantification of blood metabolites.

The next breakthrough? MSK’s Sadelain ties up with Fate on off-the-shelf CAR-Ts

John Carroll / ENDPOINTS

Fate Therapeutics is teaming up with one of the star scientists at Memorial Sloan Kettering to start work on off-the-shelf T cell therapies, one of the hottest fields in the next-gen CAR-T field.

NCI embraces scientific road map to achieve Cancer Moonshot goals

U.S. National Institute of Health

National Cancer Institute (NCI) Acting Director Douglas Lowy, M.D., today accepted the recommendations of a Blue Ribbon Panel (BRP) on 10 scientific approaches most likely to make a decade’s worth of progress against cancer in five years under the Cancer Moonshot. The report was presented by the BRP to the National Cancer Advisory Board (NCAB), and it was subsequently considered and accepted by the NCAB with revisions that reflect the NCAB’s discussion. An overview of the report was published today in the journal Science.

Repositive adds data sets, search capabilities to online genomic research platform

Nick Paul Taylor / Fierce Biotech

Repositive has introduced the full version of its online genomics data platform. The latest version gives users access to 992,000 data sets, 23 times as many as were available previously, plus search functions designed to make it easier for researchers to identify the specific data they need.

07 September 2016

Tobira Therapeutics Announces Appointment of Dr. Laurent Fischer as Industry Co-chair of the Liver Forum Steering Committee

Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced that Laurent Fischer, M.D., the company’s chief executive officer, has been appointed to serve on the Liver Forum’s steering committee. The steering committee provides overall scientific leadership to the Liver Forum. The goal of the Liver Forum is to leverage the scientific community’s collective knowledge and experience with therapies to facilitate drug development for the treatment of liver disease.

07 September 2016

Pfizer goes local with Russian joint venture

Kira Egorova / Russia Beyond the Headlines

In July 2016, the U.S. pharmaceutical giant Pfizer became the first foreign company in its sector to localize its business in Russia with a Russian partner. Pfizer and the Russian-American company NovaMedica, whose shareholders include the Russian state-owned company Rusnano, decided to jointly invest in the construction of a plant in the Kaluga Region, 125 miles southwest of Moscow.

The 10 most active VCs in healthcare

Pitch Book Blog

These past couple of weeks have seen more than a handful of massive healthcare deals. Moderna Therapeutics secured $451 million toward a planned $600 million round, Denali Therapeutics disclosed a $130 million Series B, Arcus Biosciences raised $70 million and ClearCare announced a $60 million growth financing. While tech gets the most media play, healthcare keeps chugging along.